lupus news from FierceBiotech
NewsRituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
Biogen CEO spells out interest in biotech buyout
Just days after scornfully assessing a field of weak-kneed pharma Read more...
ALSO NOTED: Avastin delivers promising data for brain cancer; Genelabs regains development rights; and much more...
> A mid-stage study of Avastin shows promising results in treating a form of brain cancer. Read more...
Aspreva agrees to $915M buyout offer
Switzerland's Galenica is buying out Canada's Aspreva Pharmaceuticals for $915 million. The deal values Aspreva's shares at $26 each, a 16 percent premium from yesterday's close. The buyout comes Read more...
Teva's lupus drug flunks Phase II
Teva says its Phase II trial for the experimental lupus drug edratide failed to hit its primary endpoint. The weekly therapy failed to cut the rate of disease activity after 26 weeks of treatments. Read more...
Aspreva, Roche put CellCept on ice
Shares of Aspreva Pharmaceuticals slipped a bit this morning after the company and Roche announced that they would not be pushing ahead with a regulatory filing for CellCept, a new therapy for lupus Read more...
Aspreva's CellCept fails late-stage superiority studyShares of Aspreva slumped today after it announced that CellCept failed a late-stage trial comparing the drug to standard lupus therapy. Aspreva and Roche are developing the drug. Response rates for both therapies were similar and did not demonstrate CellCept's superiority to intravenous cyclophosphamide--the study's primary goal. The trial included 370 volunteers. Aspreva says that it is analyzing the results as it evaluates a possible regulatory filing. - check out this … Read more...Developers testing new therapies for lupusHuman Genome Sciences is one of several developers working on a new advance for lupus. This Wall Street Journal piece looks at the pipeline for lupus, which includes programs at Bristol-Myers Squibb, Genentech and … Read more...New warning issued on Rituxan for lupusBiogen Idec and Genentech have warned doctors that two patients taking Rituxan for lupus have died of a rare brain infection called progressive multifocal leukoencephalopathy, or PML. Rituxan is approved for non-Hodgkin's lymphoma and rheumatoid arthritis and cancer patients have already been warned about their risk of PML. One analyst noted that the new risk for lupus may make it harder for the companies to gain approval to use Rituxan for lupus and M.S. Biogen Idec has also had to … Read more...HGS adds positive data in extended lupus trialAn extended mid-stage trial of Human Genome Science's lymphostat for lupus has produced new positive data on the drug. The results come a year after HGS concluded that 24-week data on 449 patients did not show that lymphostat-B reduced symptoms in the disease. In June, though, HGS announced that 52 week data did demonstrate efficacy and this new data is from 76 weeks of results on 321 patients. HGS said the response rate to the drug jumped from 46 percent to 56 percent. A late-stage trial … Read more... | Press ReleasesPRESS RELEASE: Aspreva Provides Update on Lupus Nephritis Development Program Aspreva Provides Update on Lupus Nephritis Development Program Victoria, B.C September 10, 2007 Aspreva Pharmaceuticals Corporation today announced that Aspreva and Roche have decided not to proceed Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

